Last updated: 18 November 2026
To view updates, click on the ‘+’ sign below.
Report from the CMDh meeting held on 10-12 November 2026
The reports from the CMDh meetings (also called press releases) reflect highlights/important outcomes of each meeting and are usually published in the week following the CMDh meeting. The reports therefore only contain a subsection of the complete CMDh agenda and are used for a more timely communication of the most important outcomes.
The CMDh minutes are a full record of the CMDh meetings (minus redaction of confidential content). They are adopted at the following CMDh meeting and subsequently published.
Acronyms and abbreviations used in the report and minutes are available here.
The report from the above meeting includes (but is not restricted to) the following items:
1. Call for review regarding nitrosamine impurities in humanmedicinal products
CHMP and CMDh agreed on an updated question-and-answer document on nitrosamines in November 2026.
The latest version of this document EMA/409815/2020 Rev.24 reflects several changes in the policies and recommendations published to date, such as:
- Higher AI limits for nitrosamines impurities, as a result of the full application of the less than lifetime (LTL) approach in ICH M7 for eligible medicines intended for treatments of duration of less than 10 years (see new Q&A 24)
- Extension of the CAPA implementation period from 3 to 7 years, under certain conditions (see Q&A 22)
- Inclusion of a new risk factor for nitrosamine formation linked to parenteral products packaged in polymer bags (see Q&A 4)
- Applicability of the approach to establish AI limits for nitrosamines to other N-Nitroso
compounds (see new Q&A 23) - Update on limits for nitrosamines originating from excipients (see Q&A 10)
The new Q&As have been published on the EMA website and a link is provided from the CMDh websiteunder “Nitrosamine impurities”.
- The CMDh has updated the practical guidance document for MAHs (CMDh/412/2019), the template for nitrosamine risk evaluation in marketing authorisation applications (CMDh/439/2022) and the assessment report template for step 2 scenario A responses (CMDh/431/2021), to reflect the new approaches.
- All updated documents will be published on the CMDh website under “Nitrosamine impurities”.
- For medicinal products with a duration of administration of less than 10 years the LTL adjusted AI as described in Q&A 24 should be considered when establishing the applicable step 2 scenario.
MAHs are requested to review the implications of the LTL permanent approach for any previously submitted declarations and submit an updated step 2 response template (CMDh/409/2019) where application of the new approach results in a change from scenario A to scenario B or C, including an explanation for the change in line with Q&A 24. An updated step 2 response is not required where a response changes from scenario B to scenario C.
2. Extension applications in MRP and DCP
The CMDh agreed an update to the Member States recommendations on extension applications in Mutual Recognition and Decentralised Procedures.
- Section 5 has been updated to add the exceptional situation where a MAH wants to submit a marketing authorisation application for a product that is considered a line extension in the RMS, while the originator product is not authorised in the additional CMSs.
- The updated guidance clarifies how such applications can be submitted in exceptional situations.
- The updated guidance will be published on the CMDh website under “Procedural Guidance > Application for MA”.
A link to the document will be provided here once it becomes available.
3. New applications in Mutual Recognition procedure started in October 2026
You can view the stats for the above on pages 4 and 5 of the report.
Decentralised Procedure – Requests to act as RMS
The documentwith the above title has been updated. Here, you can view the track changed (Jan 2023) and clean (November 2026) versions fo the document.
Source: HMA
Updated PLM portal eAF timeline
The update timeline for the Product Lifecycle Management (PLM) Portal electronic application form (eAF) for human variations is now available.
The timeline reflects:
- Strongly recommended use of the Human Variation eAF for non-CAP procedures from September 2025.
- Mandatory use of the Human Variation eAF for CAP procedures from September 2026*
*For details on the exceptional cases where the interactive PDF eAF remains accepted, please see the guidance.
Source: eSubmission
Fees for clinical trials submitted under the Clinical Trial Regulation (CTR) in the Clinical Trial Information System (CTIS) for EU/EEA member states
You can view the upudated document (November 2026 of the document with the above title, here.
Source: HMA
Harmonised standards – Medical Devices
Harmonised standards under the Regulations on medical devices and in vitro diagnostic medical devices are developed by CEN and CENELEC as European standardisation organisations, on the basis of a standardisation request issued by the Commission according to Regulation (EU) No 1025/2012.
For Regulation (EU) 2017/745 on medical devices:
- Commission Implementing Decision (EU) 2026/2479 of 9 November 2026
Commission Implementing Decision (EU) 2026/2479 of 9 November 2026 amending Implementing Decision (EU) 2021/1182 as regards harmonised standards for sterilization of health care products, clinical investigation of medical devices for human subjects, natural rubber latex male condoms, biological evaluation of medical devices, washer-disinfectors, medical electrical equipment and small-bore connectors for liquids and gases in healthcare applications
For Regulation (EU) 2017/746 on in vitro diagnostic medical devices:
- Commission Implementing Decision (EU) 2026/2481 of 9 November 2026
Commission Implementing Decision (EU) 2026/2481 of 9 November 2026 amending Implementing Decision (EU) 2021/1195 as regards the harmonised standard for sterilization of health care products
Updated PLM Portal eAF Release notes now available
An updated version of the PLM Portal eAF Release notes reflecting bug fixes and updates to web eAF made in the version 1.2.1.23 (released to production on 9 November 2026) is now available on the PLM portal and eSubmission PLM Portal eAF.
Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products
Rev 24 of the Q & A with the above title was published on 3 November 2026.
The following changes have been made to the document:
- Addition of Q&A 23 on the applicability of the approach to set AI for nitrosamines to other N-Nitroso compounds and
- Addition of Q&A 24 on the applicability of the LTL framework established in the ICH M7 guideline to nitrosamine impurities.
- Consequential updates to Q&As 10, 20 and 22.
- Addition of a new root cause to Q&A 4 and the approach for setting limits for nitrosamines originating in excipients in Q&A 10.
Further information on the above is available on page 5 of the CMDh Minutes for the meeting on 13-14 October 2026
Source: EMA
